Merck Sharp & Dohme B.V. Patent applications |
Patent application number | Title | Published |
20150232555 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 - Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed. | 08-20-2015 |
20140296833 | INTRAUTERINE SYSTEM FOR USE IN MEDICAL TREATMENT - An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit, and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. One or more retention elements are provided on the frame for retaining the frame within the uterus of a female mammal. | 10-02-2014 |
20140206627 | KISSPEPTIDE-PENTASACCHARIDE CONJUGATES - The invention relates to kisspeptide-pentasaccharide conjugates having the general formula (I) wherein Z | 07-24-2014 |
20140056962 | DRUG DELIVERY SYSTEM - The subject invention provides a drug delivery system comprising at least one compartment comprising (i) a drug-loaded thermoplastic polymer core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said core layer is loaded with crystals of a first (pharmaceutically) active compound and said intermediate layer is loaded with crystals of the second (pharmaceutically) active compound. | 02-27-2014 |
20140038942 | RORgammaT INHIBITORS - The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition. | 02-06-2014 |